emtricitabine has been researched along with ethinyl estradiol in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ | 1 |
1 trial(s) available for emtricitabine and ethinyl estradiol
Article | Year |
---|---|
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir | 2012 |
2 other study(ies) available for emtricitabine and ethinyl estradiol
Article | Year |
---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |